Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future

Jan Wintrich*, Ingrid Kindermann, Christian Ukena, Simina Selejan, Christian Werner, Christoph Maack, Ulrich Laufs, Carsten Tschoepe, Stefan D. Anker, Carolyn S. P. Lam, Adriaan A. Voors, Michael Boehm

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

26 Citations (Scopus)
107 Downloads (Pure)

Abstract

In contrast to the wealth of proven therapies for heart failure with reduced ejection fraction (HFrEF), therapeutic efforts in the past have failed to improve outcomes in heart failure with preserved ejection fraction (HFpEF). Moreover, to this day, diagnosis of HFpEF remains controversial. However, there is growing appreciation that HFpEF represents a heterogeneous syndrome with various phenotypes and comorbidities which are hardly to differentiate solely by LVEF and might benefit from individually tailored approaches. These hypotheses are supported by the recently presented PARAGON-HF trial. Although treatment with LCZ696 did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among HFpEF patients, subanalyses suggest beneficial effects in female patients and those with an LVEF between 45 and 57%. In the future, prospective randomized trials should focus on dedicated, well-defined subgroups based on various information such as clinical characteristics, biomarker levels, and imaging modalities. These could clarify the role of LCZ696 in selected individuals. Furthermore, sodium-glucose cotransporter-2 inhibitors have just proven efficient in HFrEF patients and are currently also studied in large prospective clinical trials enrolling HFpEF patients. In addition, several novel disease-modifying drugs that pursue different strategies such as targeting cardiac inflammation and fibrosis have delivered preliminary optimistic results and are subject of further research. Moreover, innovative device therapies may enhance management of HFpEF, but need prospective adequately powered clinical trials to confirm safety and efficacy regarding clinical outcomes. This review highlights the past, present, and future therapeutic approaches in HFpEF.

Original languageEnglish
Pages (from-to)1079-1098
Number of pages20
JournalClinical Research in Cardiology
Volume109
Issue number9
DOIs
Publication statusPublished - Sep-2020

Keywords

  • Heart failure
  • Preserved ejection fraction
  • Pharmacotherapy in HFpEF
  • LCZ696
  • Device therapy
  • PULMONARY-ARTERY PRESSURE
  • VENTRICULAR MECHANICAL DYSSYNCHRONY
  • RENAL SYMPATHETIC DENERVATION
  • EXERCISE CAPACITY
  • DIASTOLIC FUNCTION
  • SYSTOLIC FUNCTION
  • ATRIAL-FIBRILLATION
  • CARDIAC-FUNCTION
  • CARDIOVASCULAR OUTCOMES
  • RESISTANT HYPERTENSION

Cite this